Measurement method for human pancreatic lipase activity
A measurement method for human pancreatic lipase activity in a sample, includes bringing a bile acid that makes a pH for giving a maximum value of human pancreatic lipase activity to be lower than 7.7, a diglyceride and a colipase into contact with the sample at pH 7.4 or lower; and detecting a signal amount varying in accordance with the human pancreatic lipase activity in the sample, and the bile acid is a bile acid containing: one of or two or more of a-type bile acids selected from the group consisting of GDCA, GCDCA, TDCA, TCDCA and salts thereof; and/or a combination of one of or two or more of b-1-type bile acids selected from the group consisting of GCA, GUDCA, TCA, TUDCA and salts thereof, and one of or two or more of b-2-type bile acids selected from the group consisting of DCA, CDCA and salts thereof.
1. A measurement method for human pancreatic lipase activity in a blood sample, comprising:
1) maximizing the activity of human pancreatic lipase in the blood sample and decreasing the activity of human non-pancreatic lipase in the blood sample by bringing a bile acid that makes a pH for giving a maximum value of the human pancreatic lipase activity to be lower than 7.7, a diglyceride and a colipase into contact with the sample at pH 7.4 or lower; and
2) detecting a signal amount varying in accordance with the human pancreatic lipase activity in the sample,
wherein the bile acid is a bile acid comprising:
a) at least one a-type bile acid which is glycodeoxycholic acid (GDCA), glycochenodeoxycholic acid (GCDCA), taurodeoxycholic acid (TDCA), taurochenodeoxycholic acid (TCDCA), or a salt thereof; and/or
b) at least one b-i-type bile acid which is glycocholic acid (GCA), glycoursodeoxycholic acid (GUDCA), taurocholic acid (TCA), tauroursodeoxycholic acid (TUDCA), or a salt thereof, and at least one b-2-type bile acid which is deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), or a salt thereof, and
wherein when the bile acid(s) of a) is used, an addition rate of the a-type bile acid(s) is 40% or more based on a total amount of all bile acids and/or salts thereof.
2. The measurement method according to claim 1 , wherein the bile acid(s) of a) is used in said contact.
3. The measurement method according to claim 1 , wherein the bile acid(s) of b) is used in said contact.
4. The measurement method according to claim 1 , wherein the a-type bile acid(s) is glycodeoxycholic acid (GDCA), GDCA and a salt thereof, a salt of GDCA, or two salts of GDCA.
5. The measurement method according to claim 1 , wherein the a-type bile acid(s) is at least one of glycodeoxycholic acid (GDCA), taurodeoxycholic acid (TDCA), or salts thereof.
6. The measurement method according to claim 1 , wherein the a-type bile acid(s) is taurodeoxycholic acid (TDCA)), TDCA and a salt thereof, a salt of TDCA, or two salts of TDCA.
7. The measurement method according to claim 1 , wherein a non-ionic surface active agent is present together with the diglyceride.
8. The measurement method according to claim 7 , wherein the non-ionic surface active agent is at least one of polyoxyethylene alkyl ether, polyoxyethylene alkyl phenyl ether, or polyoxyethylene secondary alcohol ether.
9. The measurement method according to claim 1 , wherein a colorimetric method is employed in said detection.
10. The measurement method according to claim 1 , wherein a concentration of all bile acids is ten times or more as high as a concentration of the diglyceride in terms of a molar ratio during said contact.
11. The measurement method according to claim 1 , wherein the pH is 7.2 or lower during said contact.
12. The measurement method according to claim 1 , wherein the blood sample is taken from an individual in need of diagnosis for pancreatic disease, and wherein the measurement method further comprises:
3) diagnosing the individual in need of diagnosis of pancreatic disease as having pancreatic disease from the detected signal amount.
13. The measurement method according to claim 1 , wherein the blood sample is contaminated with a human non-pancreatic lipase and is from a heparin-administered individual.
14. A measurement method for human pancreatic lipase activity in a blood sample, comprising:
1) maximizing the activity of human pancreatic lipase in the blood sample and decreasing the activity of human non-pancreatic lipase in the blood sample by bringing a bile acid, a diglyceride and a colipase into contact with the sample at pH 7.4 or lower; and
2) detecting a signal amount varying in accordance with the human pancreatic lipase activity in the sample,
wherein a concentration of the diglyceride is 0.35 to 2.5 mmol/L, and a concentration of the bile acid is ten to twenty times as high as the concentration of the diglyceride in terms of a molar ratio, and the bile acid is:
a) at least one a-type bile acid which is glycodeoxycholic acid (GDCA), glycochenodeoxycholic acid (GCDCA), taurodeoxycholic acid (TDCA), taurochenodeoxycholic acid (TCDCA), or salts thereof, a molar ratio of the a-type bile acid(s) being 40% or more based on a total amount of all bile acids and/or salts thereof; and/or
b) at least one b-i-type bile acid which is glycocholic acid (GCA), glycoursodeoxycholic acid (GUDCA), taurocholic acid (TCA), tauroursodeoxycholic acid (TUDCA), or salts thereof, and at least one b-2-type bile acid which is deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), or salts thereof, a molar ratio of the b-1-type bile acid(s) being 30 to 70% based on the total amount of all the bile acids and/or salts thereof, and
wherein when the bile acid(s) of a) is used, an addition rate of the a-type bile acid(s) is 40% or more based on a total amount of all bile acids and/or salts thereof.
15. The measurement method according to claim 14 , wherein the bile acid(s) of a) is used in said contact.
16. The measurement method according to claim 14 , wherein the bile acid(s) of b) is used in said contact.
17. The measurement method according to claim 14 , wherein the a-type bile acid(s) is glycodeoxycholic acid (GDCA), GDCA and a salt thereof, a salt of GDCA, or two salts of GDCA.
18. The measurement method according to claim 14 , wherein the a-type bile acid(s) is at least one of glycodeoxycholic acid (GDCA), taurodeoxycholic acid (TDCA), or salts thereof.
19. The measurement method according to claim 14 , wherein the a-type bile acid(s) is taurodeoxycholic acid (TDCA), TDCA and a salt thereof, a salt of TDCA, or two salts of TDCA.
20. The measurement method according to claim 14 , wherein a non-ionic surface active agent is present together with the diglyceride.
21. The measurement method according to claim 20 , wherein the non-ionic surface active agent is at least one of polyoxyethylene alkyl ether, polyoxyethylene alkyl phenyl ether, and polyoxyethylene secondary alcohol ether.
22. The measurement method according to claim 14 , wherein a colorimetric method is employed in said detection.
23. The measurement method according to claim 14 , wherein the pH is 7.2 or lower in said contact.
24. The measurement method according to claim 14 , wherein the blood sample is taken from an individual in need of diagnosis for pancreatic disease, and wherein the measurement method further comprises:
3) diagnosing the individual in need of diagnosis of pancreatic disease as having pancreatic disease from the detected signal amount.
25. The measurement method according to claim 14 , wherein the blood sample is contaminated with a human non-pancreatic lipase and is from a heparin-administered individual.